Background. Outpatient parenteral antimicrobial therapy (OPAT) is a safe and effective method to treat serious infections in the home environment. Compared with prolonged hospitalization, OPAT has lower costs and burden on patients and caregivers. However, there is increasing evidence that outcomes with oral therapy are comparable to OPAT in some conditions. Our objective was to compare the economic burden between OPAT and oral therapy.
Background. Outpatient parenteral antibiotic therapy (OPAT) is an accepted model of care for children, as it reduces the negative psychosocial impact of hospital admission and the risk of hospital-acquired infection. However, evidence for the overall cost-effectiveness of this strategy is lacking, with the concern that OPAT may benefit healthcare providers/institutions but not patients/families. This health economic analysis aimed to address both healthcare and societal perspectives, by compare the cost-effectiveness of OPAT at home for moderate/severe cellulitis to standard hospital care.
Methods. An economic evaluation was conducted of patients recruited to a randomized control trial from January 2015 to June 2017. Children aged 6 months-18 years presenting to the emergency room (ER) with moderate/severe cellulitis were randomized to receive either intravenous antibiotics at home via OPAT or standard care in hospital. The costs considered were the OPAT service cost for the home treatment group, the inpatient admission cost for the hospital group, and costs to families. Costs were collected using hospital administrative cost data for each patient and cost questionnaires completed by parents, which included parental leave taken from work, medication and transport costs incurred. The effectiveness was measured in quality-adjusted life years (QALY) using the Child Health Utility 9D, a well-validated health-related quality-of-life assessment tool.
Results. One hundred eighty-eight children were included in the study. The total cost per patient for the healthcare institution was significantly lower for the OPAT group compared with the hospital group (US$1,136 vs. US$2,124, P < 0.001). The mean cost to a family was US$160 for the home group compared with USD$552 for the hospital group (P < 0.001), which was primarily accounted for by parents' days taken off paid work. Children's health utility was significantly higher in the OPAT group compared with the hospital group (0.86 vs. 0.75, P < 0.001). OPAT was less costly and more effective thus dominant (figure), and estimating the incremental cost-effectiveness ratio is redundant.
Conclusion. OPAT for children with moderate/severe cellulitis is less costly for both healthcare providers and families, in addition to being more effective compared with standard care to a hospital ward.
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Outpatient Parenteral Antimicrobial Therapy in Nonagenarians
Methods. The Cleveland Clinic OPAT Registry was screened to identify patients aged 90 and above discharged from hospital on OPAT. Control subjects (those aged 89 years and younger) were selected from the OPAT registry, matched to study subjects on sex, year of admission, OPAT site, vascular access, infection category, and antibiotic group. ED visits, readmissions, and deaths, for nonagenarians and controls, were described as competing outcomes. Patients were only included once. Events up to 90 days following initiation of OPAT were
